Treatment of cough in covid-19 patients
Pro Research Analysisby 
Searched over 200M research papers
COVID-19 Cough Treatment: Key Approaches and Effectiveness
Symptomatic Relief and General Management of COVID-19-Related Cough
Cough is a common symptom in both acute and post-acute COVID-19, affecting adults and children alike. The management of COVID-19-related cough varies depending on the underlying cause, and improper treatment can delay recovery or increase adverse drug reactions. For children, expert consensus highlights the importance of using cough relievers and expectorants tailored to the specific etiology, with guidance for pediatricians and general practitioners to ensure safe and effective care .
Inhaled Corticosteroids (ICS) and Combination Therapies
Several studies indicate that inhaled corticosteroids (ICS), especially when combined with long-acting beta-agonists (LABA), are among the most effective treatments for post-COVID-19 cough, particularly in cases with airway hyperresponsiveness or asthma-like symptoms. ICS/LABA therapy has shown superior effectiveness compared to other commonly prescribed medications, such as compound methoxyphenamine capsules and montelukast . While ICS may not significantly impact symptom management in all patients, they can improve lung function, especially in those with impaired pulmonary parameters post-infection . These findings are particularly relevant during the Omicron variant era, where chronic cough is often accompanied by sputum and dyspnea .
Antiviral and Add-On Therapies
For patients with asthma experiencing COVID-19-related cough, early administration of the antiviral ensitrelvir has demonstrated significant improvement in cough severity, frequency, and quality of life compared to symptomatic treatment alone . Additionally, the phytomedicine ELOM-080, which enhances mucociliary clearance, may benefit outpatients with dysfunctional mucociliary clearance by reducing coughing fits and accelerating symptom remission .
Addressing Persistent and Chronic Post-COVID-19 Cough
Persistent cough after COVID-19 is common, with a higher prevalence in females and those with abnormal laryngeal sensations, sputum production, or airway eosinophilia Alkotaji2021Chen2021. Systematic assessment and tailored treatment strategies are essential for effective management, as one-third of patients may experience cough lasting up to a year post-infection . Augmented cough reflex sensitivity and neuroinflammation are thought to underlie persistent cough, and inhaled corticosteroids are recommended for those not responding to initial symptomatic treatments .
Alternative and Adjunctive Treatments
Herbal medicines, when combined with standard Western therapies, have shown significant benefits in improving cough and sputum symptoms in COVID-19 patients, with no serious adverse events reported . Indomethacin, a nonsteroidal anti-inflammatory drug, is hypothesized to help with COVID-19-induced dry cough by counteracting bradykinin-mediated pathways, though more clinical evidence is needed .
Monitoring Treatment Effectiveness
Objective monitoring tools, such as spectral tussophonobarography, can assess changes in cough characteristics during treatment. This method has shown that, after therapy, cough sound features in COVID-19 patients can return to levels similar to healthy individuals, supporting the effectiveness of current treatment approaches .
Conclusion
The treatment of cough in COVID-19 patients requires a multifaceted approach, including symptomatic relief, targeted therapies like ICS/LABA, antivirals for specific populations, and adjunctive herbal or anti-inflammatory medications. Persistent cough post-COVID-19 is common and may require systematic assessment and individualized management. Ongoing research and larger studies are needed to further refine these strategies and validate the most effective interventions for different patient groups Dreher2025Yao2024Alkotaji2021+7 MORE.
Sources and full results
Most relevant research papers on this topic